Nuclear accumulation of mutant p53 protein: A possible predictor of failure of intravesical therapy in bladder cancer

British Journal of Urology

Volumn 79, Issue 3, 1997, Pages 373-377

  Caliskan, M ^a   Turkeri L N ^a  

^a Department of Urology ^*  (Turkey)

Author keywords

BCG therapy; Bladder neoplasms; p53; Tumour suppressor gene

Indexed keywords

BCG VACCINE; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CELL NUCLEUS; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; MALE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT FAILURE;

EID: 0031400827     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.06911.x     Document Type: Article

References (23)

1. Sarkis AS. Dalbagni G. Cordon-Cardo C et al. Association of p53 nuclear overexpression and tumour progression in carcinoma in situ of the bladder. J Urol 1994: 1 52: 388-92
2. Sidransky D. Messing E. Molecular genetics and biochemical mechanisms in bladder cancer: oncogenes. tumor suppressor genes and growth factors. Urol Clin North Am 1992: 19: 629-39
3. Thomas DJ. Robinson MC. Charlton R. Wilkinson S. Shenton BK. Neal DE. p53 expression, ploidy and progression in pTl transitional cell carcinoma of the bladder. Br J Urol 1993: 73: 533-7
4. Levine AJ, Momand J, Finlay CA. The p5 3 tumor suppressor gene. Nature 1991: 351: 453-6
5. Wright C, Thomas D. Mellon K. Neal DE. Wilson-Horne CH. Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: correlation with Ki67 index. Br I Urol 1995: 75: 173-9
6. Sarkis AS. Dalbagni G. Cordon-Cardo C et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Sail Cancer Inst 1993: 85: 53-8
7. Merz VW. Marth D, Kraft R, Ackermann DK, Zingg EJ. Studer UE. Analysis of early failures alter intravesical instillation therapy with bacille Calmette-Guèrin for carcinoma in situ of the bladder. Br J Urol 1995; 75: 180-4
8. Abel PD. Hall RR. Williams G. Should pTl transitional cell cancers of the bladder still be dassitied as superficial.' Br I Urol 1988: 62: 235-9
9. Anderstrom C. Johansson S. Nilsson S. The signilicance of lamina propria invasion on the prognosis of patients with bladder tumors. J Urol 1980; 124: 23-6
10. Cutler SJ. Heney NM, Friedell GHE. Longiludinal study of patients with bladder cancer. Factors associated with disease recurrence and progression. In Bonney WW, Prout GR Jr eds. AHA Monographs: Bladder Ca'icer. Baltimore: Williams and Wilkins. 1982: 35-46
11. Badalament RA. Ortolano V. Burers JK. Recurrent or aggressive bladder cancer: Indications for adjuvant intravesical therapy. Urol Clin North Am 1992: 19: 485-98
12. Soloway MS. Intravesical and systemic chemotherapy in the management of superficial bladder cancer. Urol Clin North Am 1984; 11: 623-35
13. Esrig D. Spruck CH, Nichols PW et id. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Am J Pathol 1993: 145: 1389-97
14. Cote R). Skinner DG. Jones PA. p53 and bladder cancer. N Eiujl J Med 1995: 532: 957-8
15. 5 Villuendas R, Piris MA, Algaa P et al. The expression of p53 protein in non-Hodgkin's lymphoma is not always dependent on p5 3 gene mutations. Blood 1993: 82: 3151-6
16. Kupryjanczyk J. Bell DA. Yandell UW. Scully RE. Thor AD. p53 expression in ovarian borderline tumors and stage I carcinomas. Am J din Pathol 1994: 102: 671-ft
17. Dosaka-Akita H. Shindoh M. Fujino M et al. Abnormal p53 expression in human lung cancer is associated with histologie subtypes and patient smoking history. Am J Clin Pathol 1994: 102: 660-4
18. Esrig I). Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. ;V Enall Med 1994: 351: 1259-64
19. Johnson S. Risberg B. Karlsson MG. Westman G. Bergstrom R. Pedersen J. p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic prognostic variables and predictive value for the local response to radical radiotherapy. Eur Ural 1995: 28: 135-42
20. Cordon-Cardo C, Melamed J. Zhang ZF et al. Detection of p53 tumor-suppressor gene protein in bladder tumors and prostate cancer: possible clinical implications. World J Ural 1994: 12: 345-351
21. Thomas D). Robinson MC. Charlton R, Wilkinson S. Shenton BK. Neal DE. P53 expression, ploidy and progression in PT1 transitional cell carcinoma of the bladder. Br I Uml 1994: 73: 533-7
22. Zhau HE. Zhao LS. Chung LWK et al. Comparative studies of prostate cancers among United States. Chinese, and Japanese patients: characterization of histopathology, tumor angiogenesis. neuroendocrine factors, and p53 protein accumulations. Urol Oncol 1995: 1: 51-63
23. Hudson MA. Nadler RB. Swanson PE, Humprey PA. p53 protein accumulation in superficial bladder cancer: a predictor of tumor progression which is not affected by intravesical BCG therapy. J Urol 1995: 153: 361A